Share on StockTwits

Research analysts at Nomura initiated coverage on shares of Akebia Therapeutics (NASDAQ:AKBA) in a report released on Monday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.

Other equities research analysts have also recently issued reports about the stock. Analysts at Credit Suisse initiated coverage on shares of Akebia Therapeutics in a research note on Monday. They set an “outperform” rating and a $25.00 price target on the stock. Separately, analysts at Morgan Stanley initiated coverage on shares of Akebia Therapeutics in a research note on Monday. They set an “overweight” rating and a $90.00 price target on the stock. Finally, analysts at UBS AG initiated coverage on shares of Akebia Therapeutics in a research note on Monday. They set a “buy” rating and a $28.00 price target on the stock.

Akebia Therapeutics (NASDAQ:AKBA) opened at 16.86 on Monday. Akebia Therapeutics has a one year low of $16.41 and a one year high of $28.50. The stock’s 50-day moving average is $19.94 and its 200-day moving average is $19.94. The company’s market cap is $308.5 million.

Akebia Therapeutics Inc is a United States-based biopharmaceutical company, which is focused on the development of small molecules for the treatment of anemia and vascular disease.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.